76 Electromagnetic Chip Bracketed vs Wire Bracketed Localization in Breast Conserving Surgery

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 56-57

76 Electromagnetic Chip Bracketed vs Wire Bracketed Localization in Breast Conserving Surgery

76 Electromagnetic Chip Bracketed vs Wire Bracketed Localization in Breast Conserving Surgery

Background/Significance

Surgical navigation and localization advancements seek to improve surgical time, total tissue excised, and the need for
re-excision in breast surgery. Bracketed localization is frequently used for procedures localizing wide or multifocal breast tumors. Electromagnetic chip (EMC) localization via Smart Clip (Elucent Medical, Madison WI) is a novel approach to clip localization. This prospective evaluation compares EMC bracketed localization to conventional wire localization in bracketed breast conserving surgery (BCS).

Materials and Methods

A prospective, institutional review board–approved single-institution cohort of female patients with breast cancer undergoing EMC bracketed localization was compared with a contemporary cohort of patients with breast cancer undergoing wire bracketed BCS. Key variables included number of localizers placed, complete retrieval of localizers, additional margins taken intraoperatively, positive malignant margins, reoperation for positive margins, time of incision to radiograph, and specimen length (mm) and volume (cm3). Statistics were performed using Kruskal-Wallis test for numerical covariates and χ2 test or Fisher exact test, where applicable, for categorical covariates.

Results

Seventy-four subjects were included, 31 with EMC localization vs 43 wire localization; of these, 10 EMC and 4 wire localized cases were oncoplastic reductions. All cases were performed by 8 fellowship-trained breast surgeons. The mean age was 66 years (range, 36-86). Mean tumor size was 41.2 mm for EMC vs 39.5 mm for wire cases (range, 12-90). Time from incision to specimen radiograph was shorter in EMC compared with wire cases, but not statistically significant. Cases with EMC had a fewer number of positive/close (<2 mm) ductal carcinoma in situ margins (29%), compared with 50% of the wire localized cases (P <.072). Specimen length and volume were also significantly lower with EMC vs wire localization (P = .029 and P = .019, respectively). Also, 93.5% of patients who underwent EMC localization had complete retrieval of localization device in the initial specimen (P = .172). Reoperation reexcision of tumor margins was required for only 29% of the EMC localized patients (P = .185). Use of the EMC localizer was also associated with a lower complication rate (6.5% vs. 9.3%; P = 1.00).

Conclusion

In this prospective, single-institution study, EMC localization was associated with fewer positive margins and smaller resection specimens in EMC bracketed BCS compared with wire bracketed procedures.

Articles in this issue

76 Electromagnetic Chip Bracketed vs Wire Bracketed Localization in Breast Conserving Surgery
76 Electromagnetic Chip Bracketed vs Wire Bracketed Localization in Breast Conserving Surgery
77 A Radio Opaque Suture May Improve Radiation Target Delineation in Post Lumpectomy Patients With Breast Cancer: A Retrospective Analysis
77 A Radio Opaque Suture May Improve Radiation Target Delineation in Post Lumpectomy Patients With Breast Cancer: A Retrospective Analysis
78 Comparison of Positive Margin Rate of Breast Cancer in Higher BMI Patients
78 Comparison of Positive Margin Rate of Breast Cancer in Higher BMI Patients
79 Case Series of Pathologic Upgrade After Reconstructive Breast Surgery
79 Case Series of Pathologic Upgrade After Reconstructive Breast Surgery
81 Assessing Recurrence Likelihood in Hormone Receptor–Positive/HER2-Negative Breast Cancer Patients Directly From MRI Using Imaging AI
81 Assessing Recurrence Likelihood in Hormone Receptor–Positive/HER2-Negative Breast Cancer Patients Directly From MRI Using Imaging AI
82 Efficacy, Safety, and Biomarker Analysis of ICARUS-BREAST01: A Phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in Patients With HR+/HER2– Advanced Breast Cancer
82 Efficacy, Safety, and Biomarker Analysis of ICARUS-BREAST01: A Phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in Patients With HR+/HER2– Advanced Breast Cancer
TPS 83 ELAINE 3: Open-Label, Randomized, Multicenter, Phase 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating Locally Advanced or Metastatic, ER+/HER2–, Breast Cancer With an ESR1 Mutation
TPS 83 ELAINE 3: Open-Label, Randomized, Multicenter, Phase 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating Locally Advanced or Metastatic, ER+/HER2–, Breast Cancer With an ESR1 Mutation
84 EQUALS: Vaginal/Sexual Health in Patients With Estrogen Receptor–Positive/HER2- Metastatic Breast Cancer
84 EQUALS: Vaginal/Sexual Health in Patients With Estrogen Receptor–Positive/HER2- Metastatic Breast Cancer
86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study
86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study
87 Elacestrant Plus Abemaciclib Combination in Patients With Estrogen Receptor-positive, HER2-Negative Advanced or Metastatic Breast Cancer
87 Elacestrant Plus Abemaciclib Combination in Patients With Estrogen Receptor-positive, HER2-Negative Advanced or Metastatic Breast Cancer
88 Eflapegrastim, a Long-Acting Granulocyte Colony–Stimulating Factor, Administered the Same Day as Chemotherapy in Patients With Early-Stage Breast Cancer: Results From a Multicenter, Open-Label Study
88 Eflapegrastim, a Long-Acting Granulocyte Colony–Stimulating Factor, Administered the Same Day as Chemotherapy in Patients With Early-Stage Breast Cancer: Results From a Multicenter, Open-Label Study
TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)
TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)
90 Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer: A Multinational and Multidisciplinary Survey—Physicians’ Perspective
90 Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer: A Multinational and Multidisciplinary Survey—Physicians’ Perspective
91 Adverse Effects and Financial Burden of Radiation Therapy in Patients With T3N0M0 Luminal Breast Cancer
91 Adverse Effects and Financial Burden of Radiation Therapy in Patients With T3N0M0 Luminal Breast Cancer
92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer
92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Related Content